Merck KGaA (MRK) Given a €115.00 Price Target at Kepler Capital Markets
Several other brokerages have also recently issued reports on MRK. JPMorgan Chase & Co. set a €95.00 ($113.10) price objective on shares of Merck KGaA and gave the company a neutral rating in a research note on Wednesday, January 10th. UBS Group set a €120.00 ($142.86) price target on shares of Merck KGaA and gave the stock a buy rating in a research note on Monday, January 8th. Warburg Research set a €115.00 ($136.90) price target on shares of Merck KGaA and gave the stock a buy rating in a research note on Thursday, November 9th. Independent Research set a €103.00 ($122.62) price target on shares of Merck KGaA and gave the stock a neutral rating in a research note on Thursday, November 9th. Finally, Berenberg Bank set a €116.00 ($138.10) price target on shares of Merck KGaA and gave the stock a buy rating in a research note on Thursday, November 9th. Twelve investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of €107.57 ($128.06).
Merck KGaA (FRA MRK) opened at €89.66 ($106.74) on Wednesday. The stock has a market cap of $11,650.00 and a price-to-earnings ratio of 21.00. Merck KGaA has a 12 month low of €87.33 ($103.96) and a 12 month high of €115.00 ($136.90).
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.